- Asia Pacific
- South Africa
- Hong Kong
- New Zealand
- Czech Republic
- United Kingdom
Recent Pfizer Press Releases
6/21/07 4:03 pm EDT
First FDA-Approved Medicine for Fibromyalgia Represents
Treatment Advance for Millions of Americans Suffering From This Chronic, Widespread Pain ConditionNEW YORK--(BUSINESS WIRE)--Pfizer announced today that the Food and Drug Administration (FDA) approved Lyrica® (pregabalin) capsules CV for the management of fibromyalgia, one of the most common chronic, widespread pain conditions in the United States. The approval of Lyrica, which received a priority review, represents a breakthrough for the more than six million Americans who suffer from this debilitating condition who previously had no FDAmore...
6/20/07 5:33 pm EDTNEW YORK--(BUSINESS WIRE)--Pfizer announced today the U.S. Food and Drug Administration (FDA) issued an approvable letter for maraviroc, which is under review as a therapy for treatment-experienced patients infected with CCR5-tropic HIV-1. We continue our discussions with the FDA to address outstanding questions and finalize the product labeling as soon as possible. Pfizer is committed to making maraviroc available to the thousands of patientsmore...
Pfizer Discontinues Clinical Trials for PF-3512676 Combined with Cytotoxic Chemotherapy in Advanced Non-Small Cell Lung Cancer6/20/07 1:50 pm EDTNEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) announced today the discontinuation of a development program in lung cancer for PF-3512676, an investigational compound, in combination with cytotoxic chemotherapy. This includes two Phase 3 clinical trials and two Phase 2 clinical trials. Pfizer licensed PF- 3512676 from Coley Pharmaceutical Group (NASDAQ: COLY) in 2005. A scheduled interim analysis of the Phase 3 clinical trials by anmore...
6/12/07 9:09 am EDT
Pfizer Launches BARC – Body Assessment Rating for CaninesNEW YORK--(BUSINESS WIRE)-- Pfizer Animal Health (NYSE: PFE) today announced that SLENTROL™ (dirlotapide), the first and only FDA-approved veterinary medication for the management of canine obesity, is now available by prescription in the United States. Slentrol was developed in response to the unmet need for a medication to help veterinarians and pet owners better manage canine obesity, an important medical condition that can leadmore...
Pfizer Invites Public to View and Listen to Webcast of Pfizer Participation at June 14 Healthcare Conference6/7/07 3:14 pm EDTNEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Olivier Brandicourt, Senior Vice President of Pfizer’s Pratt Business Unit, at the 28th Annual Goldman Sachs Health Care Conference on Thursday, June 14, at 8:40 a.m. Pacific Daylight Savings Time. To view and listen to the webcast, visit our web site homepage at www.pfizer.com and click on “themore...
Pfizer to Advance Three Key Oncology Compounds into Phase 3 Trials in 2007, Company Tells Financial Analysts6/5/07 8:00 am EDTNEW YORK--(BUSINESS WIRE)--Pfizer Inc announced that it is advancing key compounds through clinical development at a meeting with financial analysts yesterday in connection with the American Society of Clinical Oncology annual meeting (ASCO) in Chicago. The company highlighted the following oncology compounds that are currently in Phase III trials as well as additional compounds expected to advance into Phase III trials in the next year: Compoundmore...
New Data Show Pfizer's Axitinib Prolonged Overall Survival in Advanced Pancreatic Cancer When Combined with Standard of Care Chemotherapy6/4/07 9:05 am EDT
Phase II Data Examining Efficacy of Axitinib as Single-Agent and in Combination with Chemotherapies Across a Number of Tumor Types Also Presented at ASCOCHICAGO--(BUSINESS WIRE)--Pfizer announced today that axitinib (AG-013736), an investigational oral, selective inhibitor of VEGFR 1, 2,3 (vascular endothelial growth factor receptors 1, 2, 3) combined with gemcitabine showed a trend towards prolonged overall survival (OS) in patients with advanced pancreatic cancer, compared with gemcitabine alone, according to preliminary data from a randomized Phase II trial. These data were presented at themore...
Single-Agent SUTENT Prolonged Progression-Free Survival across All Advanced Kidney Cancer Patient Risk Groups, Including Those with Poorest Prognoses, Data Show6/3/07 3:00 pm EDT
Promising Anti-Tumor Activity Also Seen in Advanced Liver CancerCHICAGO--(BUSINESS WIRE)--Pfizer announced today that single-agent, oral SUTENT® (sunitinib malate) prolonged progression-free survival (PFS) across all patient risk groups, including those with the poorest prognoses for survival versus interferon-alfa (IFN-α), according to new data from the Phase III trial in the first-line treatment of advanced renal cell carcinoma (RCC). These data, along with Phase II studies of SUTENT in several tumormore...
6/2/07 6:00 pm EDT
Pfizer Research Presented at ASCO Focuses on Different Approaches to Cancer TreatmentCHICAGO--(BUSINESS WIRE)--Pfizer said today that clinical trials examining its different cancer-fighting approaches showed activity in patients with non-small cell lung cancer (NSCLC). Data on SUTENT® (sunitinib malate), as well as the investigational compounds CP-751,871 and axitinib (AG-013736), were presented at the 43rd American Society of Clinical Oncology (ASCO) Annual Meeting. “Pfizer is committed to developing innovativemore...
5/30/07 9:04 am EDTST. LOUIS & NEW YORK--(BUSINESS WIRE)--Express Scripts, Inc. (NASDAQ: ESRX), and Pfizer Inc (NYSE: PFE), today announced an agreement providing for Pfizer’s participation in Express Scripts’ rebate program. Due to improved terms under the agreement, Express Scripts has added Lipitor® (atorvastatin calcium), Pfizer’s treatment for high cholesterol and the reduction of heart attack and stroke, to its national preferredmore...